Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epidiolex in Tuberous Sclerosis Complex
NCT05864846Phase 4Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Jun 2023
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 4, open-label, single-arm trial of cannabidiol in tuberous sclerosis complex (TSC), sponsored by Jazz Pharmaceuticals plc. Primary endpoints: Numerical Rating Score within the Tuberous Sclerosis Complex Associated Neuropsychiatric Disorders Self-report, Quantified Checklist at Week 52, Tuberous Sclerosis Complex Associated Neuropsychiatric Disorders Self-report, Quantified Checklist at Week 52 and 23 more. Started Jun 2023; status: completed.
02
Drugs
cannabidiol
03
Conditions
tuberous sclerosis complex (TSC)
Beyond the preview
Go deeper on NCT05864846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05864846.